Intellia and Ultragenyx’s Clinical Updates, Novo Holdings’ Catalent Acquisition, and NanoString Bankruptcy; Simon Barnett

Episode 8 (February 9th, 2024): Intellia and Ultragenyx gave updates on their clinical trials for gene therapies for inherited rare diseases. Novo Holdings, which manages the assets of the foundation that controls Novo Nordisk, agreed to buy Catalent for $16.5 billion to keep up with the high demand for its hit drugs Wegovy and Ozempic. Spatial biology tools developer NanoString Technologies filed for bankruptcy, blaming the $31 million jury award assessed against it last November in a patent infringement case filed by rival 10x Genomics. Plus, an interview with Simon Barnett, research director at Dimension. Listed below are key references to the GEN stories, media, and other items discussed in this episode of Touching Base: Gene Therapy for Hereditary Angioedema Shows Success in Patients ·        GEN, February 5, 2024 Ultragenyx’s Gene Therapy Ameliorates Pediatric Neurodegenerative Disorder ·        By Jonathan Grinstein, GEN Edge, February 7, 2024 CRISPR-Repaired T Cells May Treat Fatal Inflammatory Diseases ·        GEN, February 5, 2024 NanoString Files for Chapter 11 Bankruptcy, Launches Strategic Review ·        By Alex Philippidis, GEN, February 5, 2024 Novo Holdings Buys Catalent for $16.5B; Sells Three Sites to Novo Nordisk for $11B ·        By Alex Philippidis, GEN, February 5, 2024 Hosted on Acast. See acast.com/privacy for more information.